Hemolytic-Uremic Syndrome Mediated by Complement: A Case Report
DOI:
https://doi.org/10.24950/rspmi.1927Keywords:
Atypical Hemolytic Uremic Syndrome, Complement Activation, Complement Inactivating Agents/ therapeutic use, Complement System ProteinsAbstract
Complement-mediated hemolytic uremic syndrome (cHUS)
is a rare syndrome that predominantly affects children and
young adults and arises from defects in the regulation of the complement cascade. We present the case of a patient who presented with a clinical picture of nausea, vomiting, diffuse abdominal pain, diarrhea, and dark urine with three days of evolution. Analytically, there were signs of microangiopathic hemolytic anemia, thrombocytopenia, and renal injury, and the patient was admitted for study. Initially treated with plasmapheresis and corticosteroids, without clinical or analytical improvement. After an exhaustive study, and with more likely diagnoses
excluded, cHUS was assumed and treatment with eculizumab was initiated with sustained recovery.
Downloads
References
Azevedo A, Faria B, Teixeira C, Carvalho F, Neto G, Santos J, et al. Portuguese consensus document statement in diagnostic and management of atypical hemolytic uremic syndrome. Port J Nephrol Hypert. 2018;32:211-32
Reis S, Ramos D, Cordinhã C, Gomes C. Desafios diagnósticos e terapêuticos na síndrome hemolítico-urêmica atípica: relato de caso. Acta Med Port. 2019;32:673-5. doi: 10.20344/amp.10021.
Manrique-Caballero CL, Peerapornratana S, Formeck C, Del Rio-Pertuz G, Gomez Danies H, Kellum JA. Typical and Atypical Hemolytic Uremic Syndrome in the Critically Ill. Crit Care Clin. 2020;36:333-56. doi: 10.1016/j.ccc.2019.11.004. .
Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaimé F, Dragon-Durey MA, Ngo S, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8:554-62. doi: 10.2215/CJN.04760512.
Santos MS, Ventura S, Alves A, Cabral R, Henriques M. The Importance of Eculizumab in the Treatment of Atypical Hemolytic Uremic Syndrome. Cureus. 2022;14:e25743. doi: 10.7759/cureus.25743.
Córdoba JMCAABEEMGMMPRTVVRd. Actualización en síndrome hemolítico urémico atípico: diagnóstico y tratamiento. Documento de consenso. Nefrología. 2015; 35:421-47. doi: 10.1016/j.nefro.2015.07.005
Yoshida Y, Kato H, Ikeda Y, Nangaku M. Pathogenesis of Atypical Hemolytic Uremic Syndrome. J Atheroscler Thromb. 2019;26:99-110. doi: 10.5551/jat.RV17026.
Macia M, de Alvaro Moreno F, Dutt T, Fehrman I, Hadaya K, Gasteyger C, et al. Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome. Clin Kidney J. 2017;10:310-9. doi: 10.1093/ckj/sfw115.
Downloads
Published
How to Cite
License
Copyright (c) 2024 Internal Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Medicina Interna
Open Access
